Cartesian Therapeutics to Participate in Upcoming Investor Conferences
06 3월 2024 - 9:00PM
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a
clinical-stage biotechnology company pioneering mRNA cell therapy
for autoimmune diseases, today announced that its management
expects to participate in the following investor conferences in
March:
- A presentation at the 2024 Leerink Partners Global Biopharma
Conference at 8:40 a.m. ET on Wednesday, March 13, 2024 in Miami,
FL
- A fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy
Virtual Conference at 11:00 a.m. ET on Tuesday, March 26, 2024
A live webcast of the presentation and fireside chat are
expected to be accessible in the Events section of the Company’s
website at www.cartesiantherapeutics.com, where an archived replay
of the events will also be available for a limited time.
About Cartesian TherapeuticsCartesian
Therapeutics is a clinical-stage company pioneering mRNA cell
therapies for the treatment of autoimmune diseases. The Company’s
lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T
in Phase 2b clinical development for patients with generalized
myasthenia gravis. Additional Phase 2 studies are planned in
systemic lupus erythematosus under an allowed IND, as well as
basket trials in additional autoimmune indications. The Company’s
clinical-stage pipeline also includes Descartes-15, a
next-generation, autologous anti-BCMA mRNA CAR-T. Cartesian
operates a wholly owned, state-of-the-art cGMP manufacturing
facility in Gaithersburg, MD. Learn more at
www.cartesiantherapeutics.com and follow us on LinkedIn and X,
formerly known as Twitter.
Contact Information:Investor
Relations:Melissa ForstArgot
Partnerscartesian@argotpartners.com
Media:David RosenArgot
Partnersdavid.rosen@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Cartesian Therapeutics (NASDAQ:RNAC)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024